Austin Health

Title
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer.
Publication Date
2023-02
Author(s)
Loft, Matthew
Lok, Sheau Wen
De Boer, Richard
Malik, Laeeq
Greenberg, Sally
Yeo, Belinda
Anton, Angelyn
Nottage, Michelle
Wong, Vanessa
Nott, Louise
Collins, Ian M
Torres, Javier
Barnett, Frances
Lombard, Janine M
Gibbs, Peter
Gately, Lucy
Subject
Endocrine therapy
HER2
Hormone receptor-positive
Metastatic breast cancer
Type of document
Journal Article
OrcId
0000-0003-3267-4520
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
DOI
10.1007/s10549-022-06856-1
Abstract
Dual anti-HER2 targeted therapy and chemotherapy is the current first-line standard of care for HER2 + metastatic breast cancer (MBC), with endocrine therapy (ET) the backbone of treatment in hormone receptor positive (HR +) disease. The potential ET benefit in HER2 + /HR + patients is unknown as pivotal dual anti-HER2 clinical trials precluded ET use.
Link
link
Citation
Breast Cancer Research and Treatment 2023; 198(1)
Jornal Title
Breast Cancer Research and Treatment
ISSN
1573-7217

Files:

NameSizeformatDescriptionLink